A Performance Overview of Johnson & Johnson’s Surgery Segment

Revenue trends

Johnson & Johnson’s (JNJ) Surgery segment reported revenues of $2.4 billion in the third quarter compared to $2.3 billion in the third quarter of 2017, reflecting ~1.3% YoY (year-over-year) growth. Johnson & Johnson’s surgery segment reported ~3.8% YoY operational growth in the third quarter.

The Surgery segment generated revenues of $1.0 billion and $1.4 billion in the US and international markets, respectively, in the third quarter, reflecting ~1.4% and ~1.2% YoY growth. In the international markets, the surgery segment reported ~5.6% YoY operational growth. Johnson & Johnson’s surgery segment’s net revenues totaled $7.3 billion over the first nine months of 2018, reflecting ~4.5% YoY growth.

A Performance Overview of Johnson & Johnson’s Surgery Segment

Advanced surgery revenue trends

Johnson & Johnson’s (JNJ) advanced surgery segment generated revenues of $976.0 million in the third quarter, including revenues of $421.0 million and $555.0 million from the US and international markets. In the US and international markets, the advanced surgery segment reported ~5.8% and ~5.7% YoY growth, respectively. Johnson & Johnson’s advanced surgery segment reported ~10.0% YoY operational growth.

General surgery revenue trends

Johnson & Johnson’s (JNJ) general surgery segment generated net revenues of $1.1 billion in the third quarter, reflecting an ~2.3% YoY decline. In the US and international markets, Johnson & Johnson’s general surgery segment generated third-quarter net revenues of $423.0 million and $657.0 million, respectively, reflecting YoY declines of ~1.6% and ~2.7%.

Specialty surgery revenue trends

Johnson & Johnson’s (JNJ) specialty surgery segment reported net revenues of $320.0 million in the third quarter compared to $318.0 million in the third quarter of 2017, reflecting ~0.6% YoY growth. In the third quarter, the specialty surgery segment reported ~2.9% YoY operational growth.

In the US and international markets, the specialty surgery division reported third-quarter net revenues of $172.0 million and $148.0 million, respectively, reflecting an ~1.1% YoY decline and 2.8% YoY growth. In the third quarter, JNJ’s specialty surgery segment reported ~7.9% YoY operational growth.

The iShares Russell 1000 Value ETF (IWD) invests ~2.32% of its total portfolio holdings in Johnson & Johnson (JNJ) stock.